https://doi.org/10.4081/reumatismo.2019.1190
Health-related quality of life burden in scleroderma patients treated with two different intravenous iloprost regimens
Accepted: 7 March 2019
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Systemic sclerosis (SSc)-related Raynaud’s phenomenon (RP) and digital ulcers (DU) can impair health-related quality of life (HRQoL). The aim of our study was to estimate HRQoL in SSc patients treated with two different intravenous (IV) iloprost (ILO) regimens and in patients not treated with IV ILO. 96 consecutive SSc patients were enrolled in a pragmatic, prospective and non-randomized study, and divided into 3 groups: not requiring therapy with IV ILO (N=52), IV ILO once monthly (N=24) or IV ILO for 5 consecutive days every 3 months (N=20). Patients were followed up for three months. We assessed HRQoL using the generic preference-based questionnaire EQ-5D-5L. We conducted multiple regression analyses to estimate, in each treatment group, the mean general health (GH) and the mean utility index of the EQ-5D-5L, adjusting for possible confounders. The mean adjusted utility index and GH score, after three months’ follow-up, were not different in the three groups: IV ILO was able to make patients requiring IV ILO similar to those not requiring it. Moreover, there was no difference in this model between the two ILO regimens (1 day monthly vs 5 consecutive days every 3 months). The two different IV ILO regimens (the most appropriate regimen was decided according to patients’ characteristics and needs) were able to stabilize HRQoL in RP secondary to SSc non-adequately controlled by oral therapy.
How to Cite
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- C. Manzo, M. Isetta, A. Castagna, Did the first description of patients with polymyalgia rheumatica take place in Scotland or in Denmark? , Reumatismo: Vol. 76 No. 1 (2024)
- L. Andreoli, F. Pregnolato, R.W. Burlingame, V. Fanelli, F. Allegri, A. Radice, C. Corace, R.A. Sinico, A. Tinconi, P.L. Meroni, Primary antiphospholipid syndrome evolving into systemic lupus erythematosus: may antinucleosome antibodies be predictive? , Reumatismo: Vol. 60 No. 3 (2008)
- M.E. Tezcan, B. Isci, Pulmonary multiple cystic lesions in a patient with Behçet’s syndrome , Reumatismo: Vol. 71 No. 2 (2019)
- O. Di Munno, A. Delle Sedie, Prevention and treatment of glucocorticoid-induced osteoporosis in International and Italian scenarios , Reumatismo: Vol. 63 No. 2 (2011)
- F. Paparo, E. Fabbro, G. Ferrero, R. Piccazzo, M. Revelli, D. Camellino, G. Garlaschi, M.A. Cimmino, Imaging studies of crystalline arthritides , Reumatismo: Vol. 63 No. 4 (2011): Special issue • Microcrystalline Arthritis
- C. Bes, O. Dikbaş, E. Keskin, Ö. Kaptanoğulları, M. Soy, A case of propylthiouracil-induced antineutrophilic cytoplasmic antibody-positive vasculitis successfully treated with radioactive iodine , Reumatismo: Vol. 65 No. 3 (2013)
- M. Rossini, O. Viapiana, M. Vitiello, N. Malavolta, G. La Montagna, S. Maddali Bongi, O. Di Munno, R. Nuti, C.U. Manzini, C. Ferri, L. Bogliolo, A. Mathieu, F. Cantatore, A. Del Puente, M. Muratore, W. Grassi, B. Frediani, G. Saviola, P. Delvino, L. Mirone, G. Ferraccioli, G. Tripi, I. Piazza, D. Gatti, Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study , Reumatismo: Vol. 69 No. 1 (2017)
- S. Parisi, A. Bortoluzzi, G.D. Sebastiani, F. Conti, R. Caporali, N. Ughi, I. Prevete, A. Ariani, M. Manara, G. Carrara, C.A. Scirè, The Italian Society for Rheumatology clinical practice guidelines for rheumatoid arthritis , Reumatismo: Vol. 71 No. S1 (2019)
- A. Lurati, R. Cimaz, M. Gattinara, V. Gerloni, B. Teruzzi, A. Salmaso, F. Fantini, Relationship between delayed menarche and bone density in patients affected by juvenile , Reumatismo: Vol. 60 No. 3 (2008)
- W.A. Wan Asyraf, M.S. Mohd Shahrir, W. Asrul, A.W. Norasyikin, O. Hanita, W.Y. Kong, M.T. Azmi, The association between serum prolactin levels and interleukin-6 and systemic lupus erythematosus activity , Reumatismo: Vol. 70 No. 4 (2018)
<< < 27 28 29 30 31 32 33 34 35 36 > >>
You may also start an advanced similarity search for this article.
